Immuron's Alcoholic Steatohepatitis (ASH) Update:
Immuron has joined forces with the US National Institute of Health to conduct a clinical trial in Alcoholic Steatohepatitis (ASH).
IMM-124E was chosen as only one of three candidates evaluated by the NIH for this fully funded trial.
The Study Headed by Virginia Commonwealth University (VCU) is a multi-centre randomized controlled study which is intended to demonstrate the efficacy of IMM-124E as a treatment for ASH compared to placebo. The study is expected to enroll 66 patients of which approximately 24 have already been randomized and dosed.